These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

809 related articles for article (PubMed ID: 36762560)

  • 1. Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study.
    Lawal OD; Aronow HD; Shobayo F; Hume AL; Taveira TH; Matson KL; Zhang Y; Wen X
    Circulation; 2023 Mar; 147(10):782-794. PubMed ID: 36762560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
    BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
    Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
    Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
    Dawwas GK; Dietrich E; Cuker A; Barnes GD; Leonard CE; Lewis JD
    Ann Intern Med; 2021 Jul; 174(7):910-919. PubMed ID: 33780291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.
    Fu EL; Desai RJ; Paik JM; Kim DH; Zhang Y; Mastrorilli JM; Cervone A; Lin KJ
    Am J Kidney Dis; 2024 Mar; 83(3):293-305.e1. PubMed ID: 37839687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
    Lau WCY; Torre CO; Man KKC; Stewart HM; Seager S; Van Zandt M; Reich C; Li J; Brewster J; Lip GYH; Hingorani AD; Wei L; Wong ICK
    Ann Intern Med; 2022 Nov; 175(11):1515-1524. PubMed ID: 36315950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
    Simon TG; Singer DE; Zhang Y; Mastrorilli JM; Cervone A; DiCesare E; Lin KJ
    Ann Intern Med; 2024 Aug; 177(8):1028-1038. PubMed ID: 38976880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.
    Xu Y; Ballew SH; Chang AR; Inker LA; Grams ME; Shin JI
    J Am Heart Assoc; 2024 Aug; 13(16):e034641. PubMed ID: 39119973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
    Jansson M; Själander S; Sjögren V; Björck F; Renlund H; Norrving B; Själander A
    J Thromb Thrombolysis; 2023 Apr; 55(3):415-425. PubMed ID: 36607464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims.
    Lip GYH; Noxon V; Kang A; Luo X; Atreja N; Han S; Cheng D; Jiang J; Abramovitz L; Deitelzweig S
    J Thromb Thrombolysis; 2024 Aug; 57(6):1092-1102. PubMed ID: 38698197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study.
    Halvorsen S; Johnsen SP; Madsen M; Linder M; Sulo G; Ghanima W; Gislason G; Hohnloser SH; Jenkins A; Al-Khalili F; Tell GS; Ehrenstein V
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):577-587. PubMed ID: 34244745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation: A Real-World Retrospective Cohort Study.
    Srikajornlarp S; Amnueypol M; Vathesatogkit P; Numthavaj P; Ungkanont A; Likittanasombat K; Pattanaprateep O; Angchaisuksiri P; Boonyawat K
    Clin Appl Thromb Hemost; 2022; 28():10760296221130058. PubMed ID: 36198021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
    J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
    Skjøth F; Larsen TB; Dun AR; Lilja M; Rahman I; Abdelgawwad K; Halvorsen S; Coleman C; Rivera M
    Am J Med; 2024 Jun; 137(6):520-528.e13. PubMed ID: 38387539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.